A Study of Cadonilimab （AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Condition:   Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy Intervention:   Drug: AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally Sponsors:   RenJi Hospital;   Ruijin Hospital;   Shanghai Zhongshan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials